FDA Approves Dectomax-CA1 for Treatment and Prevention of NWS Infestations in Cattle
U.S. Food and Drug Administration (FDA) shared on LinkedIn:
”Today, we conditionally approved the first drug for the prevention and treatment of New World screwworm (NWS) larval infestations as well as the prevention of NWS reinfestation for 21 days.
This conditional approval is limited for use in cattle and demonstrates the Agency’s dedication to rapidly facilitating access to important animal health products.”
New World Screwworm infestations, first re-emerging in Central America in 2024, have spread north through Mexico in 2025, with cases now detected as far as Nuevo Leon near the U.S. border.
The outbreak threatens regional cattle industries, prompting livestock movement restrictions, sterile fly release programs, and strict U.S.–Mexico border surveillance.
On September 30, 2025, the U.S. Food and Drug Administration conditionally approved Dectomax-CA1 for the prevention and treatment of New World screwworm (NWS) larval infestations in cattle.
The drug is available as an injectable solution and provides protection against reinfestation for up to 21 days.
Doramectin, the active ingredient, is a macrocyclic lactone that targets the parasite’s nervous system by selectively binding to glutamate-gated chloride channels.
This binding leads to hyperpolarization of nerve and muscle membranes, resulting in paralysis and death of the parasite.
Its longer half-life, due to greater lipophilicity and enhanced tissue distribution, underlies its prolonged activity, which represents a key advantage over other similar agents.
Read more on the topic here.
More on latest FDA approvals in the field of Hematology featured in Hemostasis Today.
-
Apr 11, 2026, 13:51David McIntosh: Vital Plasma Derived Medicines – The Anomalous UK Scene
-
Apr 11, 2026, 13:47Samrawit Terefe: O Negative Blood Is the Universal Donor With Extreme Scarcity
-
Apr 11, 2026, 13:39Dheeraj Garg: Rethinking Cardiovascular Disease – A Cardiologist’s Perspective
-
Apr 11, 2026, 13:37Kushal Bhatia: Is The 4.5-Hour Thrombolysis Window Officially Outdated?
-
Apr 11, 2026, 13:35William Aird: Why Did Mammalian Red Blood Cells Give Up Their Nucleus?
-
Apr 11, 2026, 13:30Ken Kuang: Gravity Is Constant, But Your Vein Health Doesn’t Have to Be
-
Apr 11, 2026, 13:21Mascha Kern: Measuring Gender’s Role in Stroke and Migraine
-
Apr 11, 2026, 13:10Danique Steeghs: Key Findings from a Microfluidic Chemiluminescent Thrombin Generation Assay
-
Apr 11, 2026, 13:06Shanvi Mahi: A Validated Tool to Explore Lived Experiences After Stroke Rehabilitation